Patient Pathway

by EMD Serono

This program offers patient support, reimbursement support, and co-pay assistance for BAVENCIO® and TEPMETKO®. BAVENCIO® (avelumab) is for patients with urothelial carcinoma (bladder cancer), kidney cancer/renal cell carcinoma (RCC), or Merkel cell carcinoma. TEPMETKO® (tepotinib) is for patients with non-small cell lung cancer (NSCLC).

Patient/Care Partner Ratings

View Online Rate it

Your feedback is important! Please add your rating and review of this resource.

Pay it forward. We are constantly updating our site, and understanding how helpful a resource was, allows us to make continuous improvements.

Was it easy to use/content easy to understand?

Did it provide you with information you were looking for, answer a question or simplify a question/issue you had?

Did you learn something new and/or did it help you make a decision?

Would you recommend to someone else?

Additional Comments:

CoverOne

Your feedback is important! Please add your rating and review of this resource.

Pay it forward. We are constantly updating our site, and understanding how helpful a resource was, allows us to make continuous improvements.